Full-Time
Assistant Laboratory Manager
Updated on 9/3/2026
IDEXX
5,001-10,000 employees
Veterinary diagnostics, lab services, software
No salary listed
No H1B Sponsorship
Portland, OR, USA
In Person
 Medical, Clinical & Veterinary |
|---|
Get referred to IDEXX
See people who can refer or advise you
- Directly supervise at least five employees in a fast-paced and/or high-volume work environment.
- Have operations leadership experience from any industry.
- Be able to work a full-time schedule that may vary based on business needs.
- Meet the physical requirements of laboratory work, including extended standing and sitting, phone and computer use, extended reach, lifting up to 50 pounds, and close, color, depth-perception, and focus-adjustment vision abilities.
- Be able to work in an environment with potential exposure to biohazards, zoonotic disease agents, and hazardous chemicals.
- Maintain reliable and dependable attendance and adhere to attendance-related policies and expectations.
- Be authorized to work for any employer in the United States.
- Serve as both a Laboratory Supervisor and an individual contributor.
- Oversee Laboratory Technicians performing work across clinical departments.
- Coach and develop employees to help them reach business goals and their full potential.
- Organize staff schedules, coordinate workflow, and oversee costs and metrics.
- Troubleshoot diagnostic analyzers and resolve workflow and turnaround-time challenges.
- Lead the lab and line of business as a business and people leader.
- Use automated analyzers, microscopes, and other laboratory diagnostic tools to perform analyses and tests supporting veterinary animal treatment.
- Perform diagnostic tests on blood, urine, fecal, and pet biopsy samples.
- Set up and run laboratory tests and read and release results according to standard operating procedures.
- Work scheduled on-site night shifts, Monday through Friday, from 4:00 a.m. to 12:30 p.m., with shifts and hours subject to business needs.
- Knowledge of human clinical or veterinary testing and procedures.
- Experience working in a laboratory.
- Experience setting up, running, and reading laboratory tests.
- Experience operating laboratory equipment, including microscopes and clinical diagnostic analyzers.
IDEXX Laboratories provides veterinary diagnostics, laboratory services, and practice management software for companion animals, livestock, and related markets. Its offerings include in-clinic diagnostic instruments and tests, centralized reference labs, and software subscriptions that streamline testing, data management, and workflows. The company differentiates itself with a vertically integrated, end-to-end ecosystem that combines clinical diagnostics, laboratory services, and software. Its goal is to improve animal health outcomes and veterinary practice efficiency through accurate testing and data-driven decision making.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Westbrook, Maine
Founded
1983
Get referred to IDEXX
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 4, 2026 Q2 revenue rose 10% to $1.22 billion, and EPS jumped 18%.
- August 28, 2026 Catalyst proBNP opened cardiac screening across cats and dogs.
- 2026 Investor Day set 2028 Cancer Dx coverage at 50% of canine cancers.
What critics are saying
- California antitrust lawsuits accuse IDEXX of exclusionary veterinary contracts and supracompetitive pricing.
- January 2026 software-defect claims tied false results to at least 40 dog deaths.
- A 2027 injunction in the antitrust case would break IDEXX's clinic lock-in model.
What makes IDEXX unique
- Catalyst, inVue Dx, and Cancer Dx lock clinics into IDEXX's installed-base workflow.
- IDEXX controls 80,000 Catalyst analyzers and over 9,000 inVue Dx placements by August 2026.
- Cloud software retention reached 105% in 2026, reinforcing recurring revenue and data moats.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Mental Health Support
Pet Insurance
Employee Stock Purchase Plan
Volunteer Paid Days Off
Growth & Insights and Company News
6 month growth
↑ 6%1 year growth
↑ 6%2 year growth
↑ 6%IDEXX Laboratories to participate in Morgan Stanley 24th Annual Global Healthcare Conference. Stock score locked: want to see it? Benzinga Rankings give you vital metrics on any stock - anytime. IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am - 11:20 am (ET). A live audio webcast of the fireside chat will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the fireside chat will be available via the same link. About IDEXX Laboratories, Inc. IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions - to advance medical care, improve efficiency, and build thriving practices. Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500(TM) Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.
IDEXX launches first dual-species point-of-care NT-proBNP test for cardiac disease in cats and dogs. Published: 28 Aug 2026 IDEXX has launched the Catalyst proBNP Test, which the organization describes as the first and only dual-driven, in-clinic test for N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker applied to assess cardiac disease in cats and dogs. The test runs on the organization's Catalyst platform, which is intended to deliver laboratory-level precision with immediate outputs. Closing A diagnostic gap in general practice. Cardiac disease affects an estimated 1 in 6 cats and 1 in 10 dogs, but the disorder is frequently underassessed in general practices, according to IDEXX. Much of that gap comes down to admission and workflow: Definitive cardiac workups often depend on echocardiography or referral to a cardiologist, resources that aren't available in each practice. Sonya Gordon, BSc, DVM, DVSc, DACVIM, professor of cardiology at the Texas A&M College of Veterinary Medicine and Biomedical Sciences, said cardiac disease can be difficult to detect early because clinical signs are often subtle or absent completely. "NT-proBNP testing provides valuable, cost-effective insight to help veterinarians identify patients with clinical or subclinical heart disease, support preanesthetic screening, and determine when additional cardiac evaluation is warranted," Gordon said in an IDEXX announcement. "A quantitative NT-proBNP assay at the point of care is an important advancement, bringing objective cardiac biomarker information closer to the patient and enabling immediate integration with the physical examination, history, and other diagnostic findings." Where the test fits in clinical workflow. According to IDEXX, the test is designed to support some common in-clinic scenarios, like detecting subclinical heart disease in cats, informing preoperative risk assessment, and evaluating the likelihood of healthcare-relevant heart changes in healthy small- and medium-breed dogs showing a heart murmur. In both species, the organization says NT-proBNP outputs support differentiating cardiac from noncardiac causes of respiratory distress, a distinction that shapes whether a patient requires cardiac workup, management, or referral vs management for a primary respiratory challenge. Outputs integrate in the VetConnect PLUS alongside a patient's presenting diagnostic history, with built-in interpretive guidance meant to support doctors in reading the NT-proBNP value in context rather than in separation. IDEXX is positioning the test as an postponement of an existing cardiac portfolio that already involves reference laboratory testing, electrocardiography, well-developed imaging, and artificial intelligence-driven diagnostic devices. According to Towards Healthcare, the Veterinary AI Diagnostics Market is projected to grow significantly, with estimates indicating the market size will increase from USD 936.06 million in 2026 to approximately USD 3917.31 million by 2035, expanding at a CAGR of 17.25% from 2026 to 2035. Artificial intelligence (AI) is progressively being applied in veterinary therapeutics for day-to-day aspects of care. From helping veterinarians in diagnostics to guiding preventive care and management planning, AI and predictive analytics are reshaping how animal health is advanced. For students preparing to enter the sector, learning how to work with these devices is becoming a significant part of thriving in the future of veterinary therapies. Novel AI-based tools automate tasks, enhance diagnostics, optimize workflow, lower workload, and improve client communication. AI-based technology is increasingly being incorporated into the everyday work of veterinary services. It can analyze a radiograph, ultrasound, or MRI with increased speed and precision. AI-based technology assists with voice-to-text healthcare record-keeping. It supports veterinary solutions by automating appointment scheduling, telemedicine, and inventory management. About IDEXX. IDEXX is a worldwide leader in pet medical care innovation. This company's diagnostic and software products and solutions create clarity in a complex and emerging world. IDEXX Laboratories, Inc., a member of the S&P 500, is a leader in pet medical care innovation, serving veterinarians globally with solutions. IDEXX Laboratories, Inc. engages in the advancement, production, and distribution of products and solutions for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates via the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment offers diagnostic and data management-driven products and services for the companion animal veterinary industry, involving in-clinic diagnostic services, outside reference laboratory solutions, and veterinary software and services. The Water segment provides innovative testing services for simple, rapid, and precise identification and quantification of different microbiological parameters in water. A recent report by Towards Healthcare highlights that the veterinary AI diagnostics market is growing, as AI-based technology contributes to disease diagnosis, accurate diagnosis with reduced errors, comprehension of intricate biological interactions, proposal of services, and improvement of challenges assessment and target-driven interventions. AI diagnostic devices for animals lower human error in imaging and lab outputs. Faster turnaround times give veterinarians more time for patient care. Early AI veterinary case research suggests advancement in consistency and precision, specifically in radiology. Predictive analytics in veterinary medicine enables earlier interventions, from tailored vaccination schedules to wellness planning. Veterinary predictive models forecast chronic disease challenges and potential outbreaks, benefiting both pets and livestock.
IDEXX Laboratories targets $45B pet diagnostics opportunity with AI, Cancer tests. August 14, 2026 Key points. * IDEXX estimates a $45 billion companion-animal diagnostics opportunity, driven by longer pet lifespans and increased preventive screening; only 13% of U.S. wellness visits currently include blood work. * The company is expanding its diagnostic portfolio with Catalyst cardiac testing, inVue Dx cytology and a broader Cancer Dx panel targeting lymphoma, mast cell tumors and hemangiosarcoma, potentially covering 50% of canine cancers by 2028. * IDEXX is investing in cloud software and AI built on billions of diagnostic and medical records, while maintaining long-term targets of more than 10% organic revenue growth, 50-100 basis points of annual margin expansion and roughly 15% average annual EPS growth. * MarketBeat previews the top five stocks to own by September 1st. IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to increase testing utilization in veterinary practices. President and CEO Mike Erickson said the company sees a long-term opportunity to expand diagnostic testing as pets live longer and veterinary practices adopt more preventive screening. He said IDEXX estimates that blood work and urinalysis identify clinically meaningful abnormalities in roughly one in four apparently healthy pets, while diagnostic testing also drives broader practice activity, including medical services, therapeutics and prescription diets. Erickson said only 13% of U.S. wellness visits currently include blood work, leaving substantial headroom for growth. IDEXX estimates that sector-wide blood-work inclusion has increased by about 50 basis points annually, contributing roughly 150 basis points of incremental recurring CAG diagnostic revenue for the company each year. Diagnostic platforms and cancer testing. The company emphasized its "Technology for Life" approach of adding new testing capabilities to existing installed instruments. IDEXX introduced quantitative proBNP cardiac testing for both dogs and cats on its Catalyst point-of-care platform. The company said the test will help veterinarians evaluate cardiac risk and make referral or monitoring decisions during patient visits. IDEXX also discussed continued adoption of its inVue Dx cytology platform. Erickson said the company had placed more than 9,000 inVue Dx instruments globally through the second quarter, with utilization per instrument in the previously stated range of $3,500 to $5,500. The platform supports ear cytology, blood morphology and fine-needle aspirate testing, or FNA. Puja Pathak, senior vice president and general manager of IDEXX VetLab, said inVue Dx is designed to reduce hands-on work, standardize results and automatically integrate findings into practice records and invoices. She said practices adopting inVue Dx have seen 6% higher ProCyte CBC utilization. IDEXX expects broad availability of the inVue FNA application by the end of the year following a controlled rollout. Discover more EV market analysis Options profit calculator The company said FNA testing on inVue Dx can enable veterinarians to assess lumps and bumps in-practice, reducing the cost and complexity associated with traditional slide preparation and outside laboratory review. According to IDEXX, practices adopting the application are examining twice as many masses. Erickson also said IDEXX plans to provide further details on MultiCue Dx, a new point-of-care diagnostic platform, at VMX in Orlando in January. He described MultiCue as complementary to the existing VetLab suite and said it was designed and manufactured at IDEXX facilities in Maine. The company did not disclose launch timing or expected economics for the platform. Cancer Dx panel expansion. Oncology was a central focus of the event. IDEXX said Cancer Dx has been used by more than 11,000 practices globally and that 70% of test runs have been paired with reference-laboratory blood-work panels. The company also said 20% of practices using Cancer Dx had another provider as their primary reference laboratory. Mike Lane, executive vice president at IDEXX, said the company will expand Cancer Dx from lymphoma detection to a multi-cancer panel. Canine mast cell tumor detection is planned for September, followed by canine hemangiosarcoma detection in December. With lymphoma, those additions are expected to address 40% of canine cancers, according to the company. IDEXX said it aims to expand panel coverage to 50% of canine cancers by 2028. IDEXX said it plans to maintain a roughly $15 price point for the multi-cancer panel when run alongside blood work through an IDEXX Reference Laboratory. Lane said the lymphoma offering can also be used for monitoring remission during CHOP chemotherapy, creating potential for recurring testing. The company characterized hemangiosarcoma as a particularly urgent unmet need because the disease can remain undetected until internal tumors rupture. Lane cited a peer-reviewed study in which more than one-third of dogs identified before rupture survived a year or longer, while no dogs identified after rupture survived one year. Software, AI and commercial expansion. Tracy Byers, senior vice president of veterinary software, diagnostic imaging and telemedicine, said IDEXX is building an integrated, cloud-based software ecosystem spanning practice management, workflow, imaging, telemedicine and pet-owner engagement. She said nearly 70% of the company's practice-management installed base is cloud-based, while net recurring revenue retention across the software ecosystem is 105%. IDEXX reported that Vello users increased 37% over the prior six months. Byers said practices using IDEXX software have higher wellness blood-work inclusion, with a further 300-basis-point increase when Vello is combined with the company's practice-management tools. The company said it is using data from 35 billion diagnostic records, more than 750 million pet-lifespan medical records and more than 650,000 annual specialist-consulting calls to develop AI capabilities. Potential applications include workflow prompts, clinical recommendations, ambient voice tools, image-quality support and disease registries. George Fennell, executive vice president of global CAG commercial, said IDEXX's commercial model is centered on helping practices manage workflow changes required to adopt new technology. The company is expanding commercial investments in Spain, France, South Korea and Canada, along with targeted additions in the U.S., to increase customer proximity and support adoption. Long-term financial framework. CFO Andrew Emerson said IDEXX expects 2026 operating profit margin to exceed 32%. The company reiterated its long-term outlook for more than 10% organic revenue growth, 50 to 100 basis points of operating-margin expansion and average annual EPS growth of about 15%. Emerson said CAG diagnostic recurring revenue has expanded about 10% annually over the past five years, adding more than $1 billion in incremental revenue. IDEXX sees potential for 8.5% to 11% long-term CAG diagnostic recurring-revenue growth excluding any recovery in clinical visits, supported by utilization, innovation, instrument placements and net price realization. The company said it expects recurring software and diagnostic-services revenue growth of more than 15%, capital revenue growth above 5%, and mid- to high-single-digit growth from its water and livestock, poultry and dairy businesses. Emerson added that IDEXX has reduced its share count by about 20% over time through share repurchases and generated 25% compounded annual free-cash-flow-per-share growth since 2015. About IDEXX Laboratories (NASDAQ:IDXX). IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide. IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider IDEXX Laboratories, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list. While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
IDEXX Laboratories has launched the Catalyst proBNP Test, the first dual-species, in-clinic test for NT-proBNP biomarker to evaluate heart disease in cats and dogs. The test runs on IDEXX's Catalyst platform, which has nearly 80,000 analyzers installed globally. The test delivers results during patient visits, reducing reliance on referrals and expanding access to cardiac assessment where specialist services are limited. It supports screening, diagnosis, and monitoring of heart disease, which affects approximately one in six cats and one in 10 dogs. IDEXX estimates the global cardiac testing opportunity at approximately $4 billion. The test will be available in North America from October 2026, with international rollout to follow.
IDEXX expands Catalyst platform into cardiac disease with first and only dual-species point-of-care NT-proBNP test. New test brings quantitative cardiac assessment for cats and dogs into everyday workflows WESTBROOK, Maine - IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst(TM) proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference...